Recent Developments in Anti-Inflammatory Therapy

1st Edition - February 17, 2023
Editors: Parteek Prasher, Flavia Zacconi, Kamal Dua, Michael Rathbone, Jeffrey Withey
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 9 8 8 - 5
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 1 4 1 6 - 1

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections… Read more

Recent Developments in Anti-Inflammatory Therapy

Purchase options

SUSTAINABLE DEVELOPMENT

Innovate. Sustain. Transform.

Save up to 30% on top Physical Sciences & Engineering titles!

Explore now

Physical science & engineering for sustainable development book covers

Institutional subscription on ScienceDirect

Request a sales quote

Advances in Anti-inflammatory Therapy explores the cutting-edge in anti-inflammation therapy in clear and concise language, with insights from academia and industry. Sections cover key regulatory pathways that mediate acute and chronic inflammation and disease onset. Further chapters are devoted to advanced anti-inflammatory pharmaceuticals, including chemical moieties, pharmacophores, APIs, natural products, herbal therapies, molecular nanomedicine and advanced drug delivery vectors. Systematically planned chapters and illustrations enable potential readers to gain essential insights on the most recent advancements in the field.

Arranged with systematic chapters covering a broad range of inflammatory diseases, discussions on past, current and future therapeutics and advanced anti-inflammatory pharmaceuticals, this book will be useful to a wide range of researchers, especially medicinal chemists, drug design experts, and biological and translational researchers working in the field of inflammation.

Cover image
Title page
Table of Contents
Copyright
Contributors
Chapter 1: Pathophysiology and pathogenesis of inflammation
Abstract
1: Introduction
2: Pathophysiology and pathogenesis of inflammation
3: Changes in vascular flow
4: Chronic inflammation
5: Arachidonic acid (AA) metabolites: Prostaglandins and leukotrienes
6: Summary
References
Chapter 2: Autoimmunity and inflammation
Abstract
1: Introduction
2: Autoimmunity: Multidirectional pathways
3: Autoimmunity and inflammation: Role of A20
4: Inflammation and autoimmunity: Granulocyte colony-stimulating factor (G-CSF) role
5: Conclusions
References
Chapter 3: Regulatory pathways of inflammation
Abstract
1: Introduction
2: Cytokine response to inflammation
3: Proinflammatory and antiinflammatory cytokines
4: Regulation of innate immune system inflammatory response
5: NF-κB pathway
6: Smad pathway
7: JAK/STAT pathway
8: MAPK pathway
9: Conclusions
References
Chapter 4: Advanced nanomedicine-based therapeutics for targeting airway inflammatory diseases
Abstract
1: Introduction
2: Inflammatory mechanisms of airway inflammatory diseases
3: Advantages and perspectives for the use of nanomedicine-based strategies in airway inflammatory diseases
4: Advanced drug-delivery systems as advanced therapeutics in airway inflammatory diseases
5: Conclusions and future directions
Declaration of competing interests
References
Chapter 5: Modulation of intestinal microbiome: Promising therapies in the treatment of inflammatory bowel disease
Abstract
Acknowledgments
1: Introduction
2: Intestinal microbiota
3: Intestinal dysbiosis
4: Transplantation of fecal microbiota
5: FMT donor screening
6: FMT in IBD
7: Limitations in FMT studies
8: FMT Adverse effects
9: Probiotics
10: Principles for the development of novel probiotic
11: Probiotics in IBD
12: Limitations of probiotics studies
13: Conclusions and further directions
References
Chapter 6: Advanced therapeutics for renal inflammation
Abstract
1: Introduction
2: Therapeutic perspective for renal inflammation
3: Novel emergence therapies for renal inflammation
4: Conclusions and future prospects for renal inflammation therapies
References
Chapter 7: Advanced therapeutics for targeting inflammatory arthritis
Abstract
1: Introduction
2: Signs and symptoms
3: Etiology
4: Epidemiology
5: Morphological changes during osteoarthritis
6: The pathogenesis of osteoarthritis
7: Advancements and current strategies in research for management of osteoarthritis
8: Conclusions
References
Chapter 8: Advanced therapeutics for targeting atherosclerosis
Abstract
1: Introduction
2: LDL-C-lowering therapy and TG-lowering therapy
3: LDL-C-lowering therapy
4: HDL-C increasing therapy
5: Angiopoietin-like 3 (ANGPTL3) inhibition
6: Immunotherapy for atherosclerosis and cardiovascular disease
7: Epigenetics in atherosclerosis
8: MicroRNAs in atherosclerosis
9: New therapeutic opportunities for atherosclerosis
10: Conclusions
References
Chapter 9: Targeting vascular inflammation in atherosclerosis with plant extracts, phytochemicals, and their advanced drug formulations
Abstract
1: Introduction
2: Plant extracts
3: Phytochemicals
4: Vitamins
5: Advanced drug delivery technology in targeting atherosclerosis
6: Conclusions
References
Chapter 10: Targeting cancer-inducing inflammation: Current advancements and future prospects
Abstract
1: Introduction
2: Inflammation and cancer
3: Current antiinflammatory therapies against cancer
4: Nanomedicine-based approach for the management of cancer
5: Antiinflammatory applications of novel drug delivery systems in cancer
6: Conclusions
Declaration of competing interest
References
Chapter 11: Interplay between gut microbiota in immune homeostasis and inflammatory diseases
Abstract
1: Introduction
2: Gut microbiota and immune system development
3: Interplay between gut microbiota, immune system, and homeostasis
4: Interplay between gut microbiota and inflammatory diseases
5: Conclusions
References
Chapter 12: Advanced drug delivery system for treating inflammation
Abstract
1: Introduction
2: How is cancer related to inflammation?
3: Cancer and antiinflammatory herbal treatments
4: Need for novel drug delivery systems
5: How are nanotechnology-based drugs most effective as cancer cures?
6: Future of nanomedicine in drug delivery
7: Conclusions
References
Chapter 13: Advanced nanoparticulate system for the treatment of antiinflammatory diseases
Abstract
1: Introduction
2: Inflammation causes
3: Inflammation therapies
4: Nanocarrier-based drug delivery systems
References
Chapter 14: Role of theranostics in targeting inflammation in chronic diseases
Abstract
1: Introduction
2: Theranostic approach
3: Conclusions
References
Chapter 15: Natural product-based antiinflammatory agents
Abstract
1: Introduction
2: Etiology and pathophysiology of inflammation
3: Treatment and its limitations
4: Natural products as antiinflammatory agents
5: Commercial value of natural resources as antiinflammatory agents
6: Conclusions and future prospects
References
Chapter 16: Mechanisms of antiinflammatory effects of naturally derived secondary metabolites
Abstract
1: Introduction
2: Secondary metabolites and their antiinflammatory activity
3: Sources of secondary metabolites
4: Isolation of secondary metabolites from plants and microorganisms
5: Mechanisms of secondary metabolite action and their value
6: Current antiinflammatory therapy based on secondary metabolites
7: Conclusion
Acknowledgment
References
Chapter 17: Antiinflammatory activity of herbal bioactive-based formulations for topical administration
Abstract
1: Introduction
2: Anatomy and physiology of skin
3: Herbal antiinflammatory agents
4: In vivo and clinical studies in herbal formulations
5: Nanocarriers
6: Gels
7: Films
8: Ointments/creams
9: Patent’s perspective
10: Conclusions and future direction
References
Chapter 18: Therapeutic potential of plant-derived flavonoids against inflammation
Abstract
1: Natural products introduction
2: Flavonoids
3: Introduction to inflammation
4: Role of flavonoids in various inflammation-associated diseases
5: Conclusions
References
Chapter 19: Heterocycles in managing inflammatory diseases
Abstract
1: Introduction
2: Mechanism of actions involved for heterocyclic scaffold-based marketed drugs in the treatment of inflammation
3: Heterocyclic scaffold-based marketed drugs in the treatment of inflammation
4: Heterocyclic scaffold-based antiinflammatory compounds under clinical development
5: Recent advancements in heterocyclic derivatives as potent antiinflammatory agents
6: Various heterocyclic scaffolds to display significant antiinflammatory activity
7: Conclusions
References
Chapter 20: In vivo models of understanding inflammation (in vivo methods for inflammation)
Abstract
1: Introduction
2: The need for antiinflammatory agents
3: The inflammatory cascade
4: Key players of inflammation
5: In vivo models of understanding inflammation
References
Further reading
Chapter 21: Clinical trials and future perspectives of antiinflammatory agents
Abstract
Acknowledgments
1: Introduction
2: Mediators of inflammation
3: Mechanism of inflammation in physiological and pathological process
4: Inflammation and immune system
5: Clinical trials of antiinflammatory drugs
6: Conclusions
References
Index

Parteek Prasher

Dr Prasher, Assistant Professor, Department of Chemistry, University of Petroleum & Energy Studies, has research experience of 8 years in medicinal chemistry and biomaterials, while working in the field of anti-inflammatory and anticancer chemotherapy. The research team led by Dr. Prasher focuses on the development of rationally designed molecules for targeting various disorders, including inflammation, cancer, and antimicrobial MDR, which also includes the Identification of novel pharmacophores, chemical moieties and APIs for developing the potential chemotherapeutics. With inspiring national/ international collaborations, Dr. Prasher has published more than 45 peer reviewed publications, and >10 book chapters in the journals of repute. Dr. Prasher serves as reviewer for reputed journals published by Elsevier, ACS, RSC and Springer publishers, with the status “Recognized reviewer”. Dr. Prasher has been a recipient of the prestigious Junior/ Senior Research Fellowship by the Council of Scientific and Industrial Research, Government of India (2012-2015). Dr. Prasher received ‘Lectureship’ award by the Government of India (2012).

Affiliations and expertise

Assistant Professor, Department of Chemistry, University of Petroleum and Energy Studies, India

Flavia Zacconi

In 2012, Prof. Zacconi became Assistant Professor in the Faculty of Chemistry at Pontificia Universidad Católica de Chile (Chile). Currently, her Associate Professor position is shared between the Faculty of Chemistry and Pharmacy and the Institute for Biological and Medical Engineering (IIBM). Moreover, Dr. Zacconi has a research experience of more than 11 years in organic chemistry, medicinal chemistry and biomaterials, while working in the field of chemical synthesis, structural analyses, drug design, and materials. Dr. Zacconi’s research focuses on the intersections of organic chemistry, medicinal chemistry, engineering and biological chemistry, developing multi- and interdisciplinary research to understand the complexity in the design, synthesis and biological evaluation of bioactive compounds. Besides, Prof. Zacconi is an Associate Researcher at the Research Center for Nanotechnology and Advanced Materials (CIEN-UC). Additionally, Dr. Zacconi acts as a reviewer for international journals and she has published research papers, book chapters, books and reviews.

Affiliations and expertise

Associate Professor, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile (PUC), Chile

Kamal Dua

Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

Affiliations and expertise

Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Michael Rathbone

Michael J. Rathbone is founder and managing director of his own company, ULTI Pharmaceuticals, New Zealand. He is also an associate of the School, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia. He was formerly professor of Pharmaceutical Technology and dean, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. Prior to this he was associate professor of Pharmaceutics, School of Pharmacy, Griffith University, Australia where his responsibilities included Acting Head of School. Previous to his appointment at Griffith University, he was the director of Research and General Manager InterAg, New Zealand, where he spearheaded the companies veterinary controlled drug delivery research and directed their national and global collaborative research activities. Dr. Rathbone obtained his undergraduate degree in Pharmacy at Leicester Polytechnic (De Montfort University), UK (1980), and PhD in Pharmaceutics from the University of Aston, Birmingham, UK (1986). Dr. Rathbone has innovated many novel veterinary drug delivery systems, several of which have been registered on the New Zealand, Australian and United States markets. He is a fellow of the Controlled Release Society, has served on the Board of Directors of the CRS and has received several prestigious awards for his contribution to the science and technology of controlled release. He has edited eight books in the area of modified release drug delivery and 10 special theme issues of journals such as Advanced Drug Delivery Reviews and Journal of Controlled Release. His knowledge of the entire spectrum of innovation, product research & development, cGMP analysis, manufacturing scale-up, QC analysis, stability testing, and registration provides him with an extensive overview, and unparalleled experience of the veterinary pharmaceutical industry.

Affiliations and expertise

ULTI Pharmaceuticals, Turangi, New Zealand

Jeffrey Withey

Professor Jeffrey Withey, PhD, has worked in the infectious diseases field for over 19 years and has held a faculty position at Wayne State University since 2006. Dr. Withey earned a Bachelor’s degree in Biology from Johns Hopkins University in 1991 and a PhD in Cellular and Molecular Biology from the University of Michigan in 2000. Dr. Withey has been awarded numerous grants from the US NIH and the Gates Foundation to fund his research. Dr. Withey was a Fulbright Scholar in 2014-2015 and was selected as a Fulbright Alumni Ambassador for 2020-2022. Dr. Withey is currently an Associate Editor for PLoS Neglected Tropical Diseases, and on the Editorial boards for Journal of Bacteriology, Infection and Immunity, Journal of Microbiological Methods, and Current Clinical Microbiology Reports. He has served on numerous grant review panels for NIH and international funding agencies and published nearly 40 research papers and several book chapters.

Affiliations and expertise

Professor, Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Recent Developments in Anti-Inflammatory Therapy

Purchase options

Innovate. Sustain. Transform.

Institutional subscription on ScienceDirect

Parteek Prasher

Flavia Zacconi

Kamal Dua

Michael Rathbone

Jeffrey Withey